Genetics and immune study of lung signet ring cell cancer
Part of Cancer, Lungs & breathing clinical trials.
This research study is looking at the unique genetic makeup and immune features of a rare type of lung cancer called signet ring cell carcinoma. By studying tumor samples and medical data, researchers hope to find better ways to understand and eventually treat this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of lung signet ring cell carcinoma (a rare type of lung cancer).
- You should not have received any treatment for this cancer before joining the study.
- Your doctor must be able to provide a sample of your tumor tissue and a piece of healthy nearby lung tissue from a biopsy or surgery.
- You need to have a life expectancy of at least 12 weeks (about 3 months).
- You must not have any other active cancer, and your signet ring cell cancer should not have started in another organ and spread to the lung.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the “molecular landscape,” meaning the specific gene changes driving your lung cancer, for people whose non-small cell lung cancer (NSCLC) has rare mutations. The goal is to better understand what those rare changes mean and how they could guide treatment decisions.
This trial looks at the genetic changes in non-small cell lung cancer (NSCLC) that has stopped responding to targeted therapy pills. It aims to understand why the cancer became resistant, which may help find better treatments.
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
Hear when a new Signet Ring Cell Carcinoma of the Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.